» Articles » PMID: 18787947

TIMP-1 Overexpression Promotes Tumorigenesis of MDA-MB-231 Breast Cancer Cells and Alters Expression of a Subset of Cancer Promoting Genes in Vivo Distinct from Those Observed in Vitro

Overview
Specialty Oncology
Date 2008 Sep 13
PMID 18787947
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

TIMP-1 (Tissue inhibitor of matrix metalloproteinase-1) is typically associated with inhibition of matrix metalloproteinases (MMP) induced invasion. However, TIMP-1 is overexpressed in many malignancies and is associated with poor prognosis in breast cancer. The mechanisms by which TIMP-1 promotes tumorigenesis are unclear. Reduced levels of TIMP-1 mediated by shRNA in MDA-MB-231 breast cancer cells had no effect on cellular physiology in vitro or tumor growth in SCID mice compared to vector control MDA-MB-231 cells. However, overexpression of TIMP-1 in MDA-MB-231 cells resulted in inhibition of cell invasion and enhanced phosphorylation of p38 MAPK and AKT in vitro. Additionally, treatment of parental MDA-MB-231 cells with purified TIMP-1 protein led to activation of p38 MAPK and MKK 3/6. cDNA array analysis demonstrated that high expression of TIMP-1 in MDA-MB-231 cells resulted in alterations in expression of approximately 200 genes, 1.5 fold or greater compared to vector control cells (P < 0.1). Real-time RT-PCR confirmed changes in expression of several genes associated with cancer progression including DAPK1, FGFR4 and MAPK13. In vivo, high TIMP-1 expression induced tumor growth in SCID mice compared to vector control cells and increased tumor vessel density. Affymetrix array analysis of vector control and TIMP-1 MDA-MB-231 xenograft tumors revealed that TIMP-1 altered expression of approximately 600 genes in vivo, including MMP1, MMP13, S100A14, S100P, Rab25 and ID4. These combined observations suggest that the effects of TIMP-1 differ significantly in a 2-D environment compared to the 3-D environment and that TIMP-1 stimulates tumor growth.

Citing Articles

The TIMP protein family: diverse roles in pathophysiology.

Coates-Park S, Rich J, Stetler-Stevenson W, Peeney D Am J Physiol Cell Physiol. 2024; 326(3):C917-C934.

PMID: 38284123 PMC: 11193487. DOI: 10.1152/ajpcell.00699.2023.


The Contribution of Tissue Inhibitor of Metalloproteinase-2 Genotypes to Breast Cancer Risk in Taiwan.

Wang Y, He J, Tsai C, Tzeng H, Chang W, Pan S Life (Basel). 2024; 14(1).

PMID: 38276258 PMC: 10817502. DOI: 10.3390/life14010009.


A straightforward method to quantify circulating mRNAs as biomarkers of colorectal cancer.

Grosgeorges M, Picque Lasorsa L, Pastor B, Prevostel C, Crapez E, Sanchez C Sci Rep. 2023; 13(1):2739.

PMID: 36792801 PMC: 9932139. DOI: 10.1038/s41598-023-29948-4.


Matrix metalloproteinases as therapeutic targets in breast cancer.

Kwon M Front Oncol. 2023; 12:1108695.

PMID: 36741729 PMC: 9897057. DOI: 10.3389/fonc.2022.1108695.


RAGE Inhibitors for Targeted Therapy of Cancer: A Comprehensive Review.

Faruqui T, Khan M, Akhter Y, Khan S, Rafi Z, Saeed M Int J Mol Sci. 2023; 24(1).

PMID: 36613714 PMC: 9820344. DOI: 10.3390/ijms24010266.